ARTICLE | Clinical News
Xifaxan rifaximin regulatory update
June 1, 2015 7:00 AM UTC
FDA approved an sNDA for Xifaxan rifaximin 550 mg tablets from Valeant to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. Valeant said the non-aminoglycoside, semi-synthetic antibiotic...